Sino Biopharmaceutical Ltd represents values of innovation, integrity, and excellence in the biopharmaceutical industry. With a commitment to improving global health, the company focuses on research, development, and commercialization of high-quality, affordable medicines. Sino Biopharmaceutical Ltd's corporate philosophy revolves around patient-centric approaches, ensuring access to innovative therapies. By leveraging their robust R&D capabilities, extensive manufacturing network, and strategic partnerships, the company aims to contribute to the well-being of patients worldwide. With a strong emphasis on ethical conduct, Sino Biopharmaceutical Ltd strives to deliver sustainable growth and create value for its stakeholders.

Sino Biopharmaceutical Ltd is primarily present in China, Hong Kong, and Macau.

Sino Biopharmaceutical Ltd, a leading pharmaceutical company, has accomplished several significant milestones in its journey. With a strong focus on innovation and research, the company has made remarkable strides in the biopharmaceutical sector. Sino Biopharmaceutical Ltd achieved the successful development and commercialization of various high-quality drugs, targeting critical therapeutic areas such as oncology, cardiovascular diseases, and infectious diseases. Additionally, the company expanded its presence globally, establishing partnerships and collaborations with renowned institutions and key players in the industry. Sino Biopharmaceutical Ltd's commitment to delivering cutting-edge healthcare solutions has garnered recognition, positioning them as a trusted and reliable leader in the pharmaceutical market.

Sino Biopharmaceutical Ltd, founded in 2000, is a well-established pharmaceutical company based in China. With a strong focus on research, development, and production of innovative drugs, Sino Biopharmaceutical has gained recognition in the global healthcare industry. Over the years, the company has emerged as a major player in the Chinese pharmaceutical market, with a diverse portfolio of products ranging from prescription drugs to over-the-counter medications. Sino Biopharmaceutical is dedicated to enhancing people's quality of life by providing high-quality and affordable healthcare solutions. Through continuous innovation and strategic partnerships, the company has achieved significant growth, making it a promising investment opportunity in the pharmaceutical sector.

The main competitors of Sino Biopharmaceutical Ltd in the market include other prominent pharmaceutical companies such as Jiangsu Hengrui Medicine Co., Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, and Beijing SL Pharmaceutical Co., Ltd. These companies are renowned for their significant presence in the pharmaceutical industry and pose strong competition to Sino Biopharmaceutical Ltd.

Sino Biopharmaceutical Ltd is primarily active in the pharmaceutical industry.

Sino Biopharmaceutical Ltd operates in the biopharmaceutical industry, specializing in the research, development, manufacturing, and distribution of pharmaceutical products. Their business model focuses on producing high-quality generic drugs, innovative biologics, and chemical drugs. Sino Biopharmaceutical aims to provide affordable and accessible healthcare solutions to patients globally. Through strategic partnerships and acquisitions, the company continuously expands its product portfolio and customer base. Sino Biopharmaceutical's dedication to technological advancements and R&D efforts strengthens its competitive advantage in the market, positioning them as a leading player in the biopharmaceutical sector.

Sino Biopharmaceutical의 P/E 비율은 20.23입니다.

Sino Biopharmaceutical의 P/S 비율은 2.09입니다.

Sino Biopharmaceutical에 대한 AlleAktien 품질 점수는 7/10입니다.

예상되는 Sino Biopharmaceutical 매출은 29.92 조. CNY입니다.

예상되는 Sino Biopharmaceutical 이익은 3.08 조. CNY입니다.

Sino Biopharmaceutical Ltd. is a pharmaceutical company based in Hong Kong that focuses on the research, development, manufacturing, and sales of pharmaceutical products. The company offers a wide range of products and services for people suffering from various diseases and health conditions. The business model of Sino Biopharmaceutical Ltd. is based on various business sectors, all of which are aimed at providing high-quality and innovative pharmaceutical products. These sectors include research and development, production and distribution of medicines, marketing and sales, biotechnology, and investment activities. The research and development department of Sino Biopharmaceutical Ltd. strives to promote innovation in drug development. The company invests heavily in the exploration of new drugs to treat diseases, including cancer, diabetes, cardiovascular diseases, and gastroenterology. The company has a strong research and development pipeline with numerous clinical trials for different drugs. The production of drugs is another important business sector of Sino Biopharmaceutical Ltd. The company has a wide range of drug production facilities, including solid dosage forms, liquid forms, and semi-solid forms. These facilities operate according to the highest international standards to ensure that the products are safe, effective, and of the highest quality. The company has a strong presence in China and also operates in the international market. It has launched a wide range of products for the treatment of various diseases. Some of the company's key products include tumor therapeutics, cardiovascular drugs, anti-infectives, digestive promoters, and the bleeding drug etamsylate. The company also has a strong marketing and sales department that is able to position and promote its products in the market. It uses a variety of distribution channels, including retail pharmacies, hospitals, physician networks, and online platforms, to sell its products. The company also has a separate biotechnology department that focuses on researching new technologies to advance medical research. It also has extensive activity in biotechnology investments. The company heavily invests in new startups and companies specializing in the development of biotechnology products. Overall, Sino Biopharmaceutical Ltd. has built a successful business model focused on providing high-quality and innovative medicines. The company has a strong presence in China and the international market, and its products are used by a wide range of customers to treat various diseases and conditions.

Sino Biopharmaceutical은(는) 연간 번의 배당을 통해 0.1 CNY의 배당금을 지급합니다.

Sino Biopharmaceutical의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Sino Biopharmaceutical의 ISIN은 KYG8167W1380입니다.

Sino Biopharmaceutical의 WKN은 A0CBDJ입니다.

Sino Biopharmaceutical의 티커는 1177.HK입니다.

지난 12개월 동안 Sino Biopharmaceutical은(는) 0.08 CNY 의 배당금을 지급했습니다. 이는 약 2.38 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Sino Biopharmaceutical은(는) 0.08 CNY의 배당금을 지급할 것으로 예상됩니다.

Sino Biopharmaceutical의 현재 배당 수익률은 2.38 %입니다.

Sino Biopharmaceutical은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Sino Biopharmaceutical은(는) 지난 26년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0.08 CNY의 배당금이 예상됩니다. 이는 배당수익률 2.47 %에 해당합니다.

Sino Biopharmaceutical은 '건강' 섹터에 속합니다.

Sino Biopharmaceutical의 마지막 배당금을 0 CNY만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Sino Biopharmaceutical는 0.1 CNY를 배당금으로 지급했습니다.

Sino Biopharmaceutical의 배당금은 CNY에 지급됩니다.